Trial Profile
A Phase 1, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105 Following Oral Administration in Healthy and Hemodialysis Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs VS 105 (Primary)
- Indications Renal failure
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Vidasym
- 02 Oct 2019 Status changed from recruiting to completed.
- 08 Feb 2017 New trial record